Nader Sanai, M.d., Susan Chang, M.d., and Mitchel S. Berger, M.d.
Journal of Neurosurgery 115:5:948-965, 2011.
In recent years, advances in the understanding of low-grade glioma (LGG) biology have driven new paradigms in molecular markers, diagnostic imaging, operative techniques and technologies, and adjuvant therapies. Taken together, these developments are collectively pushing the envelope toward improved quality of life and survival. In this article, the authors evaluate the recent literature to synthesize a comprehensive review of LGGs in the modern neurosurgical era.
Address correspondence to: Mitchel S. Berger, M.D., Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, M779, Box 0112, San Francisco, California 94143. email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
(DOI: 10.3171/2011.7.JNS10238)
